相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine
J. Sadoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
Julien Favresse et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
Fulvia Pimpinelli et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
Sarah Bird et al.
LANCET HAEMATOLOGY (2021)
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Dami A. Collier et al.
NATURE (2021)
Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients
Kristine A. Frerichs et al.
HAEMATOLOGICA (2020)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Ajai Chari et al.
BLOOD (2020)
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Maheshi N. Ramasamy et al.
LANCET (2020)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
The T Cell in Myeloma
Douglas Joshua et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Guidelines for determination of the number of prior lines of therapy in multiple myeloma
S. Vincent Rajkumar et al.
BLOOD (2015)
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Cecilie Blimark et al.
HAEMATOLOGICA (2015)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
CD19+CD24hiCD38hi B Cells Maintain Regulatory T Cells While Limiting TH1 and TH17 Differentiation
Fabian Flores-Borja et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Immunodeficiency and immunotherapy in multiple myeloma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
分享论文
